Landscape of targeted therapies for advanced urothelial carcinoma
Bladder cancer (BC) is the tenth most common malignancy globally. Urothelial carcinoma (UC) is a major type of BC, and advanced UC (aUC) is associated with poor clinical outcomes and limited survival rates. Current options for aUC treatment mainly include chemotherapy and immunotherapy. These option...
Saved in:
Main Authors: | Shihao Shang (Author), Lei Zhang (Author), Kepu Liu (Author), Maoxin Lv (Author), Jie Zhang (Author), Dongen Ju (Author), Di Wei (Author), Zelong Sun (Author), Pinxiao Wang (Author), Jianlin Yuan (Author), Zheng Zhu (Author) |
---|---|
Format: | Book |
Published: |
Open Exploration Publishing Inc.,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Revitalizing Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches
by: Maoxin Lv, et al.
Published: (2024) -
Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives
by: Irene Testi, et al.
Published: (2024) -
The rapidly changing treatment landscape of first-line advanced urothelial cancer (aUC) or metastatic urothelial cancer (mUC)
by: Minira Aslanova, et al.
Published: (2024) -
Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma
by: Ping Hu, et al.
Published: (2024) -
Metastatic urothelial carcinoma
by: Elisabeth Gómez-Moyano, et al.
Published: (2021)